PLC η2 CRISPR/Cas9 KO Plasmid (h): sc-409214
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PLC η2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PLC η2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PLC η2 CRISPR/Cas9 KO Plasmid (h) | sc-409214 | 20 µg | $397.00 |
Overview
PLCH2 encodes phospholipase C eta 2 (PLC η2), a phosphoinositide-specific enzyme that hydrolyzes PIP2 to generate IP3 and diacylglycerol, thereby coupling membrane lipid signaling to intracellular Ca2+ mobilization and protein kinase C activation. As a modulator of phosphoinositide turnover, PLC η2 contributes to Ca2+-dependent control of signal transduction, cytoskeletal remodeling, and vesicle trafficking in human cells. Altered PLC-linked lipid signaling is broadly relevant to dysregulated proliferation, differentiation, and stress responses, making PLCH2 a useful node for interrogating pathway rewiring in disease-associated cellular phenotypes. Studying PLC η2 can help resolve how PIP2/IP3/DAG dynamics shape downstream transcriptional programs and calcium-dependent effector networks.
PLC η2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PLCH2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PLCH2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PLCH2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PLC η2 protein expression.
This CRISPR knockout system enables efficient generation of PLCH2-deficient cell models for investigation of PLC η2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PLCH2 exon(s) critical for PLC η2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PLCH2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PLC η2 CRISPR/Cas9 KO Plasmid (h) and PLC η2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PLCH2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PLC η2 HDR Plasmid (h) and PLC η2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PLCH2 homology arms to support homology-directed repair at defined PLCH2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.